Strength in Foldable Smartphones Keeps Us Bullish on This Portfolio Play

Universal Display (OLED) is poised for continued growth as Samsung's U.S. market share surged to 31% and its Galaxy Z Fold 7 saw 25% higher preorders and nearly 50% stronger sales than previous models, underscoring the accelerating adoption of foldable technology and OLED displays. Concurrently, Labcorp (LH) launched the nationwide availability of its FDA-cleared Lumipulse pTau-217/Beta Amyloid 42 Ratio test, a blood-based diagnostic for Alzheimer's disease, which offers a cost-competitive and comparable alternative to existing methods, aligning LH with the aging population investment theme. Investors are also anticipating insights from upcoming Google Pixel events and investor conferences featuring Marvell (MRVL).

Analysis

While the market anticipates direction from geopolitical meetings and upcoming macro data like the August PMI, several portfolio-relevant catalysts are emerging at the company level. Universal Display (OLED) is benefiting from a significant acceleration in the foldable smartphone market, underscored by Samsung's U.S. market share surging from 23% to 31% and its latest Galaxy Z Fold 7 achieving 25% greater preorders and nearly 50% stronger sales than its predecessor. This trend supports the thesis for OLED's continued growth, with potential further validation expected from Google's upcoming Pixel 10 event. This event is also being watched for its AI feature unveilings, which has implications for network capacity and, by extension, portfolio holding Marvell (MRVL). In the healthcare sector, Labcorp (LH) has launched its nationwide, FDA-cleared blood-based diagnostic test for Alzheimer's disease, the Lumipulse pTau-217/Beta Amyloid 42 Ratio. This test offers a cost-competitive and less invasive alternative to existing diagnostic methods, positioning Labcorp to capitalize on the secular aging population trend. Despite this positive development, the analysis notes that with just over 10% upside to its $300 target, a more favorable entry point would be near the $260 level. Near-term catalysts for several tech names, including MRVL, AMD, and GLW, will be their respective management presentations at the Citi and Goldman conferences in early September.

Key Decisions for Investors

• Given the strong, quantifiable momentum in foldable smartphone adoption directly benefiting Universal Display, investors should monitor the upcoming Google Pixel event for further validation of this growth trend and its impact on the OLED ecosystem.
• The nationwide launch of Labcorp's FDA-cleared Alzheimer's blood test is a significant commercial catalyst; investors could consider the current valuation with approximately 10% upside to the $300 target, or await a potential pullback near the $260 level for a more favorable risk-reward entry.
• Pay close attention to management presentations from Marvell, AMD, and Corning at the Citi and Goldman conferences in early September, as these events are timed to provide fresh forward-looking insights less than a month before the quarter's end.